Zevalin On Track For Medicare ASP-Based Reimbursement In 2010
This article was originally published in The Pink Sheet Daily
Change to average sales price based payment for Cell Therapeutics’ radioimmunotherapy could help boost use in community oncology centers.
You may also be interested in...
New indication sought in sBLA could mean whopper sales, CTI exec says.
The Pharmaceutical Research and Manufacturers of America expressed support for using an average sales price-based approach to reimbursing radiopharmaceuticals under Medicare in response to CMS' statement of its willingness to consider switching from reimbursement based on individual hospitals' claims
Two key drugs likely to be affected by such a change are Cell Therapeutics’ Zevalin and GlaxoSmithKline’s Bexxar.